New York, NY (PRWEB) July 06, 2014
A joint transvaginal mesh (http://www.injurybeacon.com/transvaginal-mesh/) status conference is scheduled to take place later this month in the U.S. District Court, Southern District of West Virginia, where several federal litigations are currently underway, Bernstein Liebhard LLP reports.
According to court documents posted on the Court’s website, the joint conference will take place on July 24, 2014 at 10:00 a.m., to discuss lawsuits filed against companies such as C.R. Bard Inc., (MDL No. 2187), American Medical Systems (No. 2325), Boston Scientific Corp. (MDL No. 2326), and the Johnson & Johnson subsidiary, Ethicon (MDL No. 2327).
More than 50,000 lawsuits have now been filed by women who allegedly suffered mesh erosion, infection, chronic pain as well as pain during sexual intercourse, and other complications necessitating revision surgery to remove transvaginal mesh, a surgical material used to repair such condition as pelvic organ prolapse (POP) and stress urinary incontinence (SUI) in women.
“We are pleased to see these transvaginal mesh litigations moving forward in the Southern District of West Virginia, as our Firm is actively filing cases in these proceedings,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case reviews to women who allegedly experienced mesh erosion, pain, scarring, infection and other serious side effects following their implantation of transvaginal mesh.
Transvaginal Mesh Lawsuits
As multidistrict litigations involving transvaginal mesh lawsuits look ahead to their upcoming status conferences, court documents reflect their continued progress in the Southern District of West Virginia. As of June 16th, court records show more than 18,000 claims now pending in the federal proceeding involving Ethicon products, while more than 17,800 claims have now been filed against American Medical Systems
Jeffrey S. Grand, a partner at Bernstein Liebhard LLP is actively serving on the Plaintiffs’ Steering Committee in the above litigations, as well as those involving C.R. Bard and Boston Scientific. (Federal and state-filed transvaginal mesh lawsuits have continued to increase over the past few years, following a series of safety alerts from the U.S. Food and Drug Administration (FDA), according to court records. The federal agency’s first warning was issued in 2008, at which time regulators determined the risk for transvaginal mesh complications to be “rare.” After logging more than 3,000 adverse event reports from women who allegedly experienced pain, infection, mesh erosion and other side effects, the FDA published a second alert in 2011 that re-categorized the risk as “not rare.”
All mesh lawsuits now pending in West Virginia federal court similarly accuse manufacturers of designing, manufacturing and marketing implants that were defective, and increase a woman’s likelihood of sustaining serious injuries that may permanently diminish her overall quality of life. Vaginal mesh manufacturers also failed to adequately warn women and their doctors about side effects that may be associated with their products, plaintiffs allege.
Women who suffered serious vaginal mesh complications allegedly due to transvaginal mesh may be entitled to compensation. Learn more about the process of filing a transvaginal mesh lawsuit when you visit Bernstein Liebhard LLP's website or the Firm's Facebook page: https://www.facebook.com/meshlawsuit. To obtain a free, confidential and no-obligation case review, please call (888) 340-4807.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP